Eli Lilly announced promising results for its next-generation obesity drug, letaltortide, revealing it achieved the highest weight loss ever recorded in a late-stage trial. Participants experienced an average weight loss of 23.7% over 68 weeks, with those continuing treatment losing up to 28.7%. The drug also reduced knee arthritis pain significantly, with an average decrease of 62.6% and many patients experiencing complete resolution of pain.
Despite these advances, 18% of participants discontinued treatment due to side effects, which included nausea, diarrhea, and nerve sensations; however, these were generally mild. Letaltortide functions by mimicking three hunger-regulating hormones, offering a more robust appetite suppression compared to existing drugs.
Eli Lilly is banking on letaltortide as a cornerstone of its obesity treatment portfolio, competing heavily in a market projected to reach $100 billion by the 2030s. The company plans to share results from additional Phase 3 trials by the end of 2026. Eli Lilly’s main competitor, Novo Nordisk, is also advancing its obesity medications, including a drug that similarly mimics multiple hormones, but it is still in early development stages.
Source link
